WO1994028142A1 - N-methyltransferase de putrescine, molecules d'adn de recombinaison codant cette derniere, et plants de tabac transgeniques a teneur reduite en alcaloides - Google Patents
N-methyltransferase de putrescine, molecules d'adn de recombinaison codant cette derniere, et plants de tabac transgeniques a teneur reduite en alcaloides Download PDFInfo
- Publication number
- WO1994028142A1 WO1994028142A1 PCT/US1994/006106 US9406106W WO9428142A1 WO 1994028142 A1 WO1994028142 A1 WO 1994028142A1 US 9406106 W US9406106 W US 9406106W WO 9428142 A1 WO9428142 A1 WO 9428142A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pmt
- seq
- tobacco
- putrescine
- sequence
- Prior art date
Links
- 235000002637 Nicotiana tabacum Nutrition 0.000 title claims abstract description 115
- 108091022910 Putrescine N-methyltransferase Proteins 0.000 title claims abstract description 15
- 244000061176 Nicotiana tabacum Species 0.000 title claims description 115
- 230000009261 transgenic effect Effects 0.000 title claims description 28
- 108020004511 Recombinant DNA Proteins 0.000 title claims description 16
- 230000003247 decreasing effect Effects 0.000 title description 6
- 229930013930 alkaloid Natural products 0.000 title description 5
- 150000003797 alkaloid derivatives Chemical class 0.000 title description 3
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims abstract description 62
- 239000005700 Putrescine Substances 0.000 claims abstract description 31
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 17
- 241000208125 Nicotiana Species 0.000 claims abstract 3
- 108090000623 proteins and genes Proteins 0.000 claims description 73
- 102000004169 proteins and genes Human genes 0.000 claims description 53
- 150000001413 amino acids Chemical group 0.000 claims description 44
- 239000002299 complementary DNA Substances 0.000 claims description 23
- 239000013598 vector Substances 0.000 claims description 14
- 108020005544 Antisense RNA Proteins 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 claims description 10
- 229960001570 ademetionine Drugs 0.000 claims description 10
- 238000012546 transfer Methods 0.000 claims description 7
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 2
- 102000053602 DNA Human genes 0.000 claims 6
- 108020004414 DNA Proteins 0.000 claims 3
- 238000000034 method Methods 0.000 abstract description 56
- 238000005349 anion exchange Methods 0.000 abstract description 50
- 239000012149 elution buffer Substances 0.000 abstract description 27
- 239000000284 extract Substances 0.000 abstract description 25
- 238000000746 purification Methods 0.000 abstract description 23
- 230000008569 process Effects 0.000 abstract description 15
- 241001002356 Valeriana edulis Species 0.000 abstract description 14
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 241000196324 Embryophyta Species 0.000 description 49
- 235000018102 proteins Nutrition 0.000 description 45
- 239000002609 medium Substances 0.000 description 43
- 230000000694 effects Effects 0.000 description 41
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 38
- 230000000692 anti-sense effect Effects 0.000 description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- 235000001014 amino acid Nutrition 0.000 description 32
- 102000004190 Enzymes Human genes 0.000 description 29
- 108090000790 Enzymes Proteins 0.000 description 29
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 29
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 29
- 235000011130 ammonium sulphate Nutrition 0.000 description 29
- 229940088598 enzyme Drugs 0.000 description 29
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 28
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 24
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 24
- 229960002715 nicotine Drugs 0.000 description 24
- 239000013615 primer Substances 0.000 description 24
- 150000003839 salts Chemical class 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 239000000499 gel Substances 0.000 description 21
- 239000000463 material Substances 0.000 description 20
- 239000000872 buffer Substances 0.000 description 19
- 239000012634 fragment Substances 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 17
- 239000006167 equilibration buffer Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000001155 isoelectric focusing Methods 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 16
- 239000007983 Tris buffer Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 13
- 238000010828 elution Methods 0.000 description 13
- 239000011536 extraction buffer Substances 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000010561 standard procedure Methods 0.000 description 13
- RMIVMBYMDISYFZ-UHFFFAOYSA-N N-methylputrescine Chemical compound CNCCCCN RMIVMBYMDISYFZ-UHFFFAOYSA-N 0.000 description 12
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 12
- 239000000419 plant extract Substances 0.000 description 12
- 229920002684 Sepharose Polymers 0.000 description 11
- 238000012300 Sequence Analysis Methods 0.000 description 11
- 239000006172 buffering agent Substances 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 230000036961 partial effect Effects 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- 239000002738 chelating agent Substances 0.000 description 10
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical group BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 10
- 229910001385 heavy metal Inorganic materials 0.000 description 10
- 239000003638 chemical reducing agent Substances 0.000 description 9
- 239000003184 complementary RNA Substances 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 229920002401 polyacrylamide Polymers 0.000 description 8
- 229920000768 polyamine Polymers 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 238000000108 ultra-filtration Methods 0.000 description 8
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical group CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 7
- -1 36.0 kD Proteins 0.000 description 7
- 241000701489 Cauliflower mosaic virus Species 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 238000005194 fractionation Methods 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 7
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000000717 retained effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- HZZIFFOVHLWGCS-KKUMJFAQSA-N Asn-Phe-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O HZZIFFOVHLWGCS-KKUMJFAQSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- QPVFUAUFEBPIPT-CDMKHQONSA-N Phe-Gly-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O QPVFUAUFEBPIPT-CDMKHQONSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 238000003277 amino acid sequence analysis Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 230000005030 transcription termination Effects 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- 229920002271 DEAE-Sepharose Polymers 0.000 description 5
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 5
- 108010052968 leupeptin Proteins 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 5
- 150000002989 phenols Chemical class 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 4
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 4
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 4
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 4
- 108010059820 Polygalacturonase Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 239000000287 crude extract Substances 0.000 description 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 108010060641 flavanone synthetase Proteins 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 210000004897 n-terminal region Anatomy 0.000 description 4
- 239000002751 oligonucleotide probe Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 101150053681 pmt gene Proteins 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 4
- 241000589158 Agrobacterium Species 0.000 description 3
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 3
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 241000227653 Lycopersicon Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 101710167853 N-methyltransferase Proteins 0.000 description 3
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000005571 anion exchange chromatography Methods 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 210000001938 protoplast Anatomy 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- AHVYPIQETPWLSZ-UHFFFAOYSA-N 1-methyl-2,5-dihydropyrrole Chemical compound CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 2
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 2
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 2
- BKDDABUWNKGZCK-XHNCKOQMSA-N Asn-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)N)N)C(=O)O BKDDABUWNKGZCK-XHNCKOQMSA-N 0.000 description 2
- PBVLJOIPOGUQQP-CIUDSAMLSA-N Asp-Ala-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O PBVLJOIPOGUQQP-CIUDSAMLSA-N 0.000 description 2
- WSGVTKZFVJSJOG-RCOVLWMOSA-N Asp-Gly-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O WSGVTKZFVJSJOG-RCOVLWMOSA-N 0.000 description 2
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 2
- 102000003846 Carbonic anhydrases Human genes 0.000 description 2
- 108090000209 Carbonic anhydrases Proteins 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- AIGROOHQXCACHL-WDSKDSINSA-N Glu-Gly-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O AIGROOHQXCACHL-WDSKDSINSA-N 0.000 description 2
- ZMVCLTGPGWJAEE-JYJNAYRXSA-N Glu-His-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)O)N)O ZMVCLTGPGWJAEE-JYJNAYRXSA-N 0.000 description 2
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 2
- GWCRIHNSVMOBEQ-BQBZGAKWSA-N Gly-Arg-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O GWCRIHNSVMOBEQ-BQBZGAKWSA-N 0.000 description 2
- NNCSJUBVFBDDLC-YUMQZZPRSA-N Gly-Leu-Ser Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O NNCSJUBVFBDDLC-YUMQZZPRSA-N 0.000 description 2
- WMGHDYWNHNLGBV-ONGXEEELSA-N Gly-Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WMGHDYWNHNLGBV-ONGXEEELSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 102000008192 Lactoglobulins Human genes 0.000 description 2
- 108010060630 Lactoglobulins Proteins 0.000 description 2
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 238000009004 PCR Kit Methods 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 240000007377 Petunia x hybrida Species 0.000 description 2
- YCCUXNNKXDGMAM-KKUMJFAQSA-N Phe-Leu-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YCCUXNNKXDGMAM-KKUMJFAQSA-N 0.000 description 2
- CDHURCQGUDNBMA-UBHSHLNASA-N Phe-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 CDHURCQGUDNBMA-UBHSHLNASA-N 0.000 description 2
- 108010065081 Phosphorylase b Proteins 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 2
- XUDRHBPSPAPDJP-SRVKXCTJSA-N Ser-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO XUDRHBPSPAPDJP-SRVKXCTJSA-N 0.000 description 2
- CQNFRKAKGDSJFR-NUMRIWBASA-N Thr-Glu-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O CQNFRKAKGDSJFR-NUMRIWBASA-N 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- PDSLRCZINIDLMU-QWRGUYRKSA-N Tyr-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PDSLRCZINIDLMU-QWRGUYRKSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 108010045023 alanyl-prolyl-tyrosine Proteins 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 239000012501 chromatography medium Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 2
- 229950007919 egtazic acid Drugs 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 108010075431 glycyl-alanyl-phenylalanine Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000004382 potting Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000012772 sequence design Methods 0.000 description 2
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000724252 Cucumber mosaic virus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IMXSCCDUAFEIOE-UHFFFAOYSA-N D-Octopin Natural products OC(=O)C(C)NC(C(O)=O)CCCN=C(N)N IMXSCCDUAFEIOE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- IMXSCCDUAFEIOE-RITPCOANSA-N D-octopine Chemical compound [O-]C(=O)[C@@H](C)[NH2+][C@H](C([O-])=O)CCCNC(N)=[NH2+] IMXSCCDUAFEIOE-RITPCOANSA-N 0.000 description 1
- 108010066133 D-octopine dehydrogenase Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- INCJJHQRZGQLFC-KBPBESRZSA-N Leu-Phe-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O INCJJHQRZGQLFC-KBPBESRZSA-N 0.000 description 1
- HGNRJCINZYHNOU-LURJTMIESA-N Lys-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(O)=O HGNRJCINZYHNOU-LURJTMIESA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 101100301141 Nicotiana plumbaginifolia RBCS gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- KAAPNMOKUUPKOE-SRVKXCTJSA-N Ser-Asn-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KAAPNMOKUUPKOE-SRVKXCTJSA-N 0.000 description 1
- OSFZCEQJLWCIBG-BZSNNMDCSA-N Ser-Tyr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OSFZCEQJLWCIBG-BZSNNMDCSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- YUWBVKYVJWNVLE-UHFFFAOYSA-N [N].[P] Chemical compound [N].[P] YUWBVKYVJWNVLE-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000010310 bacterial transformation Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 108010002685 hygromycin-B kinase Proteins 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007169 ligase reaction Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000003976 plant breeding Methods 0.000 description 1
- 210000000745 plant chromosome Anatomy 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000010666 regulation of catalytic activity Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000002786 root growth Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007226 seed germination Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
Definitions
- the present invention relates to highly purified putrescine N-methyltransferase, to a novel process for its purification, and to its antisense and sense genes.
- this invention relates to the use of the sense and antisense putrescine
- N-methyltransferase genes to create transgenic tobacco plants having genetically altered nicotine levels. Such transgenic plants are useful in the production of cured tobacco for use in the tobacco industry.
- Nicotine, and biologically synthesized compounds in general are formed through sequences of biochemical reactions, wherein each reaction is catalyzed by a different enzyme.
- the particular reaction sequence leading to a given compound is known as a pathway.
- One approach for inhibiting the operation of a pathway, and thus output of its end product, is reducing the amount of a required enzyme in the pathway. If the enzyme's abundance, relative to the other enzymes of the pathway, is normally low enough to make that enzyme rate-limiting in the pathway's operation, then any reduction in the enzyme's abundance will be reflected in lowered production of the end product. If the enzyme's relative abundance is not normally rate limiting, its abundance in the cell would have to be reduced sufficiently to make it rate-limiting, in order for the pathway's output to be diminished. Similarly, if the enzyme's relative abundance is rate limiting, then any increase in its abundance will result in increased production of the pathway's end product.
- Nicotine is formed primarily in the roots of the tobacco plant and subsequently is transported to the leaves, where it is stored (Tso, Physiology and Biochemistry of Tobacco Plants, pp. 233-34, Dowden, Hutchinson & Ross, Stroudsburg, PA (1972)).
- the nicotine molecule is comprised of two heterocyclic rings, a pyridine moiety and a pyrrolidine moiety, each of which is derived from a separate biochemical pathway.
- the pyridine moiety of nicotine is derived from nicotinic acid.
- the pyrrolidine moiety of nicotine is provided through a pathway leading from putrescine to N-methylputrescine and then to N-methylpyrroline.
- PMT N-methyltransferase
- S-adenosylmethionine serving as the methyl group donor.
- PMT appears to be the rate-limiting enzyme in the pathway supplying N- methylpyrroline for nicotine synthesis in tobacco (Feth et al., "Regulation in Tobacco Callus of Enzyme Activities of the Nicotine Pathway", Planta, 168, pp. 402-07 (1986); Wagner et al., "The Regulation of Enzyme Activities of the Nicotine Pathway in Tobacco", Physiol. Plant.. 68, pp. 667-72 (1986)).
- an antisense RNA molecule is one whose nucleotide sequence is complementary to some portion of the target mRNA molecule.
- the antisense RNA molecule thus, will undergo complementary base pairing (hybridization) with the target mRNA molecule, rendering the target mRNA molecule unavailable for translation, more susceptible to degradation, or both. The ability of the cell to produce the specific enzyme coded for by the target mRNA is thus inhibited.
- Antisense technology has been employed in several laboratories to create transgenic plants characterized by lower than normal amounts of specific enzymes. For example, plants with lowered levels of chalcone synthase, an enzyme of a flower pigment biosynthetic pathway, have been produced by inserting a chalcone synthase antisense gene into the genome of tobacco and petunia. These transgenic tobacco and petunia plants produce flowers with lighter than normal coloration (Van der Krol et al., "An Anti-Sense Chalcone Synthase Gene in Transgenic Plants Inhibits Flower Pigmentation", Nature. 333, pp. 866-69 (1988)).
- Antisense RNA technology has also been successfully employed to inhibit production of the enzyme polygalacturonase in tomatoes (Smith et al., “Antisense RNA Inhibition of Polygalacturonase Gene Expression in Transgenic Tomatoes", Nature, 334, pp. 724-26 (1988); Sheehy et al., “Reduction of Polygalacturonase Activity in Tomato Fruit by Antisense RNA", Proc. Natl. Acad. Sci. USA. 85, pp.
- transgenic plants characterized by greater than normal amounts of a given enzyme may be created by transforming the plants with the gene for that enzyme in the sense (i.e., normal) orientation.
- Genetic engineering of tobacco plants to lower or raise levels of nicotine through altered levels of PMT has not been possible, because a method for cloning PMT genes without prior purification of the PMT enzyme is not known, and a method for purification of the PMT enzyme was not known prior to this invention.
- FIGURES Figure 1 is a reproduction of a photograph of a 12.5%, silver-stained, SDS-polyacrylamide gel showing the pattern of proteins obtained at successive stages of the tobacco PMT purification process.
- Lanes 1 and 6 molecular weight standard proteins (phosphorylase B, 95.5 kD; glutamate dehydrogenase, 55.0 kD; ovalbumin, 43.0 kD; lactate dehydrogenase, 36.0 kD, carbonic anhydrase, 29.0 kD; lactoglobulin, 18.4 kD; cytochrome C, 12.4 kD) .
- Lane 2 40-65% ammonium sulfate fraction.
- Lane 3 PMT activity peak fraction from hydrophobic interaction column.
- Lane 4 concentrated putrescine- eluted material from anion exchange column.
- Lane 5 PMT activity peak fraction from free-flow isoelectric focussing of concentrated material from anion exchange column.
- Figure 2 is a graph depicting PMT activity in sequential 3 mm slices from a 12.5% non-denaturing polyacrylamide gel, onto which had been loaded concentrated putrescine-eluted material from an anion exchange column. Enzymatic activity of PMT is expressed as 14 C disintegrations per minute (above background) recovered as product, and designated "relative activity”.
- Figure 3 is a reproduction of a photograph of a silver-stained 12.5% SDS-polyacrylamide gel on which successive 3 mm slices in and around the band of PMT activity on a non-denaturing electrophoresis gel ( Figure 2) were analyzed for purity and apparent molecular weight. Lane designated “sm” contains starting material (i.e., material applied to the nondenaturing gel).
- Lanes designated “std” contain molecular weight standard proteins (phosphorylase B, 95.5 kD; glutamate dehydrogenase, 55.0 kD; ovalbumin, 43.0 kD; lactate dehydrogenase, 36.0 kD, carbonic anhydrase, 29.0 kD; lactoglobulin, 18.4 kD; cytochrome C, 12.4 kD) .
- Figure 4 is a graph depicting relative PMT activity and pH of fractions obtained by isoelectric focussing of tobacco PMT purified via ammonium sulfate fractionation, hydrophobic interaction chromatography, and putrescine elution from an anion exchange column followed by sample concentration. Enzymatic activity of PMT is expressed as 14 C disintegrations per minute (above background) recovered as product, and is designated "relative activity”.
- Figure 5 is a reproduction of a photograph of a 12.5%, silver-stained, SDS-polyacrylamide gel showing the PMT protein bands ("al” and "a2") that were cut out (after electroblotting onto an inert membrane) and subjected to amino acid sequence determination.
- Samples loaded onto the gel were aliquots from fractions from isoelectric focussing of putrescine-eluted material from an anion exchange column.
- the actual bands used for sequence analysis were from a separate (but similar) polyacrylamide gel that was loaded with aliquots of the same material analyzed on the gel in this figure.
- the present invention provides, for the first time, highly purified putrescine N-methyltransferase ("PMT”) , and a novel process for its purification.
- PMT putrescine N-methyltransferase
- the purification process of this invention comprises the step of applying a tobacco plant extract to an anion exchange medium, wherein the application temperature and the pH and composition of the extract are such that PMT is retained by the anion exchange medium.
- the PMT is then eluted from the anion exchange medium with an elution buffer comprising an effective amount of a polyamine, wherein the elution temperature and the pH and chemical composition of the elution buffer are such that but for the polyamine, the PMT would be retained by the anion exchange medium.
- the eluate of the anion exchange medium is concentrated by directly applying the eluate to a chromatography medium having an affinity for PMT in the presence of the anion exchange medium elution buffer, and then eluting the bound material.
- the outlet from the anion exchange column is connected to the inlet of an omega- aminohexyl agarose column, on which dilute PMT from the anion exchange column is collected, for subsequent elution in a more concentrated form.
- the PMT of this invention has a molecular weight of between about 55 and 65 kilodaltons, a native isoelectric point of between about pH 5.0 and 6.0, a K,,.
- the PMT comprises a sequence of 17 amino acids selected from the amino acid sequences defined in the Sequence Listing as SEQ ID NO:l, SEQ ID NO:2, and SEQ ID NO:3.
- the present invention also provides sense and antisense recombinant DNA molecules encoding putrescine N-methyltransferase, and vectors comprising those recombinant DNA molecules, as well as transgenic tobacco cells and plants transformed with those DNA molecules and vectors.
- the transgenic tobacco cells and plants of this invention are characterized by lower or higher nicotine content than untransformed control tobacco cells and plants.
- Starting material for purification of PMT consists of tobacco roots.
- the roots are harvested from hydroponically grown tobacco plants.
- Hydroponic cultivation facilitates growth of the plants under highly controlled, reproducible conditions, and it allows efficient harvest of the extensive, filamentous root system in a clean, intact condition.
- Tobacco seeds are allowed to germinate at or near the surface of a moist plant potting mixture. Most preferred conditions are about 80°F and 60% relative humidity. About two weeks after seed germination, seedlings are thinned (removed) to leave sufficient room for unhindered growth of the remaining seedlings to a stage at which they are about six inches tall, and have about six leaves. When the seedlings reach a height of about six inches they are typically transplanted, with root system and pellet of potting material intact, into a hydroponic device containing a suitable nutrient solution and a means for aeration (oxygenation) of the nutrient solution.
- the hydroponic device also should provide for replenishment of the dissolved nutrients, and should be of a size sufficient to accommodate a fully grown tobacco plant. It is well known in the art that removal of the flower head (topping) , a standard practice in commercial tobacco cultivation, increases root growth and increases nicotine content of the leaves. Therefore, plants to be used as a starting material for purification of PMT normally are topped at an appropriate stage of development. The appropriate interval separating planting and topping depends on several factors including, inter alia, plant variety, light intensity, photoperiod, soil and air temperatures, soil moisture, and mineral nutrition. Typically, however, the roots are harvested 3 to 7 days after topping. The optimal time for topping a given tobacco variety cultivated under a given set of growing conditions can readily be determined by one of ordinary skill in the art.
- the harvested roots are washed with cold water, and then residual water is removed by aspiration in a Buchner funnel.
- the washed roots are then either used fresh, or frozen at -80°C immediately after harvesting.
- the frozen roots are stored at about -80°C until use.
- the extraction buffer typically contains effective amounts of one or more buffering agents, one or more reducing agents, one or more heavy metal chelating agents, one or more water activity modifying agents, and one or more protease inhibitors.
- the extraction buffer also will contain an effective amount of one or more phenolic compound adsorbing agents.
- the effective amounts of these agents depends on the particular agents used; however, amounts used generally will be chosen from among the typical amounts used during purification of plant proteins. The choice of agents and their effective amounts is, thus, well within the skill of the ordinary worker.
- the pH of the extraction buffer should be between about 7.2 and 8.3, and preferably about 7.5. Any water-soluble compound that has a dissociation constant (P ⁇ a ) giving it effective pH buffering capacity at the desired pH may be used.
- Preferred buffering agents are also essentially transparent to ultraviolet light. Suitable buffering agents include, inter alia, tris(hydroxymethyl)aminomethane (“Tris”) , iraidazole, phosphate, N-morpholinopropane sulfonic acid (“MOPS”) , N-tris(hydroxymethyl)methyl-2-aminoethane sulfonic acid (“TES”) , triethanolamine, and N-tris(hydroxymethyl)- methyl-glycine (“Tricine”) . Tris buffer is preferred.
- Reducing agents are added to the extraction buffer in order to inhibit possible oxidation of protein sulfhydryl groups, and possible oxidation of plant phenolic compounds to reactive free radicals, both of which events might inactivate PMT.
- Suitable reducing agents include, inter alia, dithiothreitol ("DTT") , dithioerythritol, 2-mercaptoethanol, thioglycolate, glutathione, cysteine, and ascorbate. DTT and ascorbate are preferred.
- Heavy metal chelating agents are added to the extraction buffer in order to prevent activation of proteases and possible inactivation of PMT by heavy metals through direct interaction with PMT or through promotion by the metals of oxidation of phenolics to species that inactivate PMT.
- the preferred heavy metal chelating agent is ethylene diaminetetraacetic acid (“EDTA”) , but other conventional chelating agents, such as ethylene glycol bis(beta-aminoethyl ether) N,N,N',N'- tetraacetic acid (“EGTA”) and citrate, may be used.
- Water activity modifying agents are added to the extraction buffer in order to stabilize PMT against possible denaturation and other more subtle conformational changes that might result in PMT inactivation.
- Such water activity modifying agents are non-ionic, hydrophilic compounds that lower the water activity of an aqueous solution to which they are added.
- Glycerol, ethylene glycol, and low molecular weight polyethyleneglycol are preferred, but glucose, sucrose, fructose, and sorbitol are examples of other compounds useful as water activity modifying agents.
- Protease inhibitors usually are added to the extraction buffer in order to prevent possible inactivation of PMT through proteolytic cleavage by proteolytic enzymes that may be released during tissue homogenization.
- useful protease inhibitors include, inter alia, phenylmethylsulfonyl fluoride ("PMSF") , leupeptin, aprotinin, chymostatin and pepstatin. PMSF and leupeptin are preferred.
- a phenolic compound adsorbing agent preferably is added to the extraction buffer to remove phenolic plant compounds that might, if present, inactivate or precipitate PMT following their oxidation when the plant cells are broken.
- PVPP polyvinylpyrrolidone
- Amberlite XAD-4 Amberlite XAD-4
- PVPP polyvinylpyrrolidone
- Amberlite XAD-4 Amberlite XAD-4
- the extraction buffer Prior to addition of the root tissue, the extraction buffer is cooled to between about -15 and -20°C to form a frozen slurry. During the homogenization process, the temperature of the homogenate should not be allowed to rise above about 3 to 5°C.
- the quantity of root tissue used in the process can be varied, but the approximate weight of the tissue used should be measured, and the amounts of other components used adjusted accordingly.
- insoluble material including PVPP with adsorbed phenolics
- insoluble material preferably is removed from the homogenate. Preferably, this is accomplished by sedimentation for between about 30 to 90 minutes at about 4°C, in a refrigerated centrifuge set at about 10,000 to 20,000 x g.
- the soluble extract i.e., the supernatant
- the final protein concentration of the soluble extract is generally about 2.5 to 3.5 mg/ml.
- the soluble extract is subjected to ammonium sulfate fractionation, and a 40% to 65% ammonium sulfate fraction (precipitate) is collected from the soluble extract according to standard methods (Scopes, Protein Purification Principles and Practice, pp. 48-52, Springer-Verlag, New York (1982)). That fraction then is dissolved in about 0.1 to 0.4 ml of a dissolution buffer per g of root weight.
- the preferred buffer for dissolution of the 40% to 65% ammonium sulfate fraction contains effective amounts of a buffering agent, a heavy metal chelating agent, a reducing agent, a water activity-modifying agent, and protease inhibitors.
- the most preferred dissolution buffer contains Tris buffer (pH about 7.5) (about 10 to 20 mM) , EDTA (about 1 to 10 mM) , glycerol (about 10 to 30%) , DTT (about 1 to 10 mM) , PMSF (about 0.2 to 10.0 mg/1) , and leupeptin (about 0.2 to 10.0 mg/1) .
- Tris buffer pH about 7.5
- EDTA about 1 to 10 mM
- glycerol about 10 to 30%
- DTT about 1 to 10 mM
- PMSF about 0.2 to 10.0 mg/1
- leupeptin about 0.2 to 10.0 mg/1 .
- ammonium sulfate fraction may then be desalted by standard techniques — e.g., dialysis or sieving chromatography — and the desalted fraction directly subjected to anion exchange chromatography, as described below. In a preferred embodiment, however, the ammonium sulfate fraction first is subjected to hydrophobic interaction chromatography.
- salt is added to give a salt concentration that is high enough to ensure that PMT binds to the hydrophobic interaction medium.
- concentration of added salt is 1.5 N.
- the preferred added salt is NaCl.
- Another useful salt is ammonium sulfate.
- the preferred hydrophobic interaction medium comprises approximately spherical particles of cross- linked agarose gel, of a size suitable for chromatography, bearing covalently bonded phenyl groups.
- phenylagarose is commercially available as "phenyl- Sepharose CL-4B" (Phar acia-LKB, Inc., Piscataway, NJ, Cat. No. 17-0810-01) .
- Hydrated phenylagarose is packed into a suitable chromatography column using standard procedures, and is equilibrated at about 4 to 8°C with a high salt equilibration buffer having a pH of from between about 7.2 to 8.3, and preferably about 7.5.
- the preferred high salt equilibration buffer contains effective amounts of a buffering agent, a heavy metal chelating agent, a water activity modifying agent, a reducing agent, and salt at a concentration of between about 1.5 to 2.0 M.
- the most preferred high salt equilibration buffer solution contains about 10 mM Tris (pH about 7.5), about 1.5 M NaCl, about 1 mM EDTA, about 2 mM DTT, and about 20% (v/v) glycerol.
- a sample of the salt-adjusted soluble extract (about 0.5 to 2.0 ml of extract per ml phenylagarose packed bed volume) is loaded onto the equilibrated phenylagarose column, and the column is washed with the equilibration buffer until the eluate becomes essentially free of proteinaceous material. If the buffering agent is transparent to ultraviolet light, this may be determined by measuring ultraviolet light absorbance at around 280 nm. Generally, the phenylagarose column is washed with about 5 to 7 column volumes of equilibration buffer. PMT remains bound to the hydrophobic interaction medium.
- Proteins still adsorbed to the phenylagarose matrix are then eluted at 4 to 8°C with between about 4 to 6 column volumes of an elution buffer containing a linear salt gradient decreasing from the load salt concentration (preferably about 1.5 M) to about 0.0 M, followed by an additional 2 to 3 column volumes of elution buffer without salt.
- the elution buffer will include Tris (about 10 mM) (pH about 7.5), DTT (about 2 mM) , and EDTA (about 1 mM) , and glycerol (about 20% v/v) .
- Fractions of between about 0.01 to 0.03 column volumes are collected and assayed for PMT activity as described below and for absorbance at 280 nm.
- the pooled eluate fractions have a volume of between about 1 to 2 column volumes, and a protein concentration of between about 0.4 and 2.5 mg/ml.
- salts other than the preferred NaCl may be used in the foregoing buffers.
- Such salts include potassium chloride and ammonium sulfate.
- the critical step of the purification process of this invention is a novel anion exchange chromatography step, performed as described below.
- the tobacco plant extract applied to the column e.g., preferably, the phenylagarose eluate
- the tobacco plant extract applied to the column must have a pH and chemical composition such that the PMT in the extract will bind to the anion exchange medium.
- the extract should have a pH of between about 7.2 and 8.3, comprise between about 0.0 and 10 mM salt, and preferably should further comprise the following: between about 5 and 15 mM of a buffering agent, between about 1 and 10 mM of a reducing agent, between about 10 and 30% (v/v) of a water activity modifying agent, and between about 1 and 5 mM of a heavy metal chelating agent.
- the tobacco plant extract comprises 10 mM Tris/HCl, pH 7.5, 2 mM DTT, 1 mM EDTA and 20% (v/v) glycerol.
- the pH and salt concentration of the tobacco plant extract may be varied in concert from the values recited above, resulting in a load condition at which the PMT still will bind to the anion exchange medium.
- an increase in salt concentration generally will decrease the binding of a protein to an anion exchange medium and an increase in pH generally will increase binding of a protein to an anion exchange medium.
- the skilled worker therefore, could easily determine various combinations of salt concentration and pH, other than those recited above, at which PMT will bind to the anion exchange medium.
- the only constraint on the possible pH/salt concentration combinations is that the pH may not be so high as to denature and inactivate PMT. Generally, PMT should not be exposed for significant periods of time to a pH above about 9.
- the tobacco root extract to be applied to the anion exchange medium is an ammonium sulfate fraction or the eluate from the above-described hydrophobic interaction chromatography step, then it must be desalted into an appropriate buffer.
- This may be accomplished by any standard technique. For example, gel filtration chromatography (using, e.g., Sephadex G-25) or dialysis may be employed, using well known procedures. Preferably, such desalting will be accomplished by dialysis.
- the pooled eluate from the above hydrophobic interaction chromatography step (or another high salt tobacco root extract) is dialyzed at about 4 to 8°C against a dialysis buffer with about 15 to 25 ml dialysis buffer per ml of pooled eluate or extract, for about 8 to 20 hours.
- the dialysis buffer will be stirred.
- a dialysis membrane having a 10,000 kD cut-off is preferred.
- the chemical composition and pH of the dialysis buffer is chosen so that PMT in the dialyzed fraction will be retained by the anion exchange medium, as described above.
- the anion exchange medium should consist of relatively rigid particles (e.g., crosslinked agarose) , of a size suitable for chromatography, that bear one or more functional anion exchange moieties.
- Such anion exchange moieties may be selected, inter alia, from the group consisting of diethylaminoethyl, polyethylene- imino, tertiary amino, quaternary amino, p-aminobenzyl, and diethyl-(2-hydroxypropyl)aminoethyl.
- Such media are commercially available.
- An anion exchange medium bearing diethylaminoethyl (“DEAE") moieties is preferred.
- DEAE-agarose (“DEAE-Sepharose, Fast Flow", Pharmacia-LKB, Inc., Piscataway, NJ, Cat. No. 17-0709- 01) is most preferred.
- the anion exchange medium is equilibrated to the pH and salt condition of the equilibration buffer, according to standard procedures.
- the equilibrated anion exchange medium then is packed according to standard procedures into a column (i.e., a hollow tube) having at its bottom a means of retaining the medium (e.g., a sintered glass disk) and an outlet tube.
- the top of the column is then covered and connected to an inlet tube.
- equilibration buffer should be run through the column, and the pH and conductivity of the flowthrough monitored, to ensure that the medium is properly equilibrated.
- the column should contain enough anion exchange medium so that the proteins in the tobacco plant extract to be applied would occupy no more than about 50% of the medium's capacity if they all were to bind.
- the tobacco plant extract to be applied is the above-described dialyzed phenylagarose eluate
- the column should contain about 0.04 to 0.10 ml (packed bed volume) of DEAE-agarose per ml of dialyzed phenylagarose eluate.
- the column is packed and the medium equilibrated at the same temperature at which the tobacco plant extract is to be applied. If the column is to be washed or eluted at a warmer temperature than that at which the tobacco plant extract is applied, then the slurry containing the anion exchange matrix may be degassed prior to packing the column.
- the anion exchange medium equilibration buffer must have a pH and chemical composition such that PMT is retained by the medium. Similarly, the skilled worker easily may determine suitable pH/chemical composition combinations.
- the preferred equilibration buffer contains essentially no added salt and has a pH of between about 7.2 to 8.3, most preferably 7.5.
- a more preferred equilibration buffer contains effective amounts of a buffering agent, a heavy metal chelating agent, a reducing agent, and a water activity modifying agent.
- the most preferred equilibration buffer contains 10 mM Tris/HCl (pH 7.5), 1 mM EDTA, 2 mM DTT, and 20% (v/v) glycerol.
- the tobacco plant extract, the equilibration buffer and the anion exchange medium are all at a temperature of between about 2 to 10°C, and most preferably between about 4 to 8°C before and during equilibration, loading, and washing of the column.
- the tobacco plant extract is applied at a flow rate of between about 0.1 to 0.3 column volumes/min.
- the flowthrough from the tobacco plant extract application contains practically no PMT, and is discarded.
- the column is then washed with equilibration buffer until elution of proteinaceous material stabilizes at a low level.
- the column is washed with elution buffer until the UV absorbance at 280 nm stabilizes at a low level.
- the anion exchange medium is washed with 5 to 12 column volumes of equilibration buffer with 10 mM NaCl, and then another 3 to 10 column volumes of equilibration buffer without NaCl. PMT is retained by the anion exchange medium during the washing step.
- PMT is eluted from the anion exchange medium with an elution buffer comprising an effective amount of a polyamine, wherein the elution temperature and the pH and chemical composition of the elution buffer are such that but for the polyamine, the PMT would be retained by the anion exchange medium.
- the polyamine in the elution buffer is selected from the group consisting of putrescine, N- methylputrescine, spermine, spermidine, agmatine, cadaverine, and mixtures thereof. Putrescine is the preferred polyamine.
- the polyamine should be present in the elution buffer at a concentration of between about 0.5 to 50 mM, preferably 1 to 10 mM, and most preferably at about 5 mM.
- the elution buffer preferably further comprises effective amounts of a buffering agent, a heavy metal chelating agent, a reducing agent, and a water activity modifying agent.
- a buffering agent preferably a buffering agent, a heavy metal chelating agent, a reducing agent, and a water activity modifying agent.
- Those components are as described above for the extraction buffer. The effective amounts of these components may be determined without undue experimentation by the skilled worker.
- the pH of the elution buffer should be between about 7.2 and 8.3, preferably about 7.5.
- the anion exchange medium equilibration buffer when supplemented with a polyamine, is a suitable elution buffer.
- a preferred elution buffer contains 10 mM Tris/HCl (pH 7.5), 1 mM EDTA, 20% (by volume) glycerol, 2 mM DTT, and 5 mM putrescine (1,4-diaminobutane) (Sigma Chemical Co., St. Louis, MO, Cat. No. P7505) .
- Elution of PMT from the anion exchange column is preferably carried out at between about 18 to 26°C (i.e., room temperature).
- the elution buffer and the anion exchange column should be at the chosen elution temperature before elution is commenced.
- elution buffer is applied at a flow rate of between about 0.02 to 0.10 column volumes/min, and fractions are collected from the bottom of the column.
- the eluate also may be collected into a single eluate pool.
- approximately one column volume of elution buffer is applied to the column, and the flow is then stopped.
- the anion exchange medium is left in contact with that aliquot of elution buffer for between about 1 to 6 hours, preferably about one hour.
- Application of elution buffer is then recommenced. PMT elutes from the anion exchange medium very gradually.
- the anion exchange medium is eluted with between about 40 and 70 column volumes of elution buffer, and most preferably at least 50 column volumes of elution buffer.
- PMT activity of eluted fractions is assayed, as described below, to monitor PMT elution.
- the anion exchange eluate may, for example, be applied to any chromatography medium which has an affinity for PMT in the presence of the anion exchange medium elution buffer, and from which the bound material can be eluted with good yield in a relatively concentrated form.
- the PMT may be precipitated.
- the outlet from the anion exchange column, during elution is connected to the inlet of the concentration column. In this way, the eluted PMT runs out of the anion exchange column and directly onto the concentration column, where it is adsorbed.
- the preferred concentration column utilizes omega-aminohexyl agarose ("omega-aminohexyl-Sepharose 4B", Sigma Chemical Co., St. Louis, MO, Cat. No. A8894) ("AHS"), with a bed volume 10 to 30% that of the anion exchange column.
- AHS omega-aminohexyl agarose
- the PMT is eluted from this column with an elution buffer comprising a relatively high concentration of salt, preferably 1.5 M NaCl.
- the elution buffer further comprises effective amounts of a buffering agent, a heavy metal chelating agent, a reducing agent, and a water activity modifying agent.
- the most preferred elution buffer comprises 1.5 M NaCl, 10 mM Tris/HCl (pH 7.5), 1 mM EDTA, 20% (v/v) glycerol, and 2 mM DTT.
- the concentration column is preferably loaded and eluted at 4-8°C. The first 4 to 8 column volumes of eluate from the concentration column contains the majority of the PMT activity. This fraction is further concentrated, preferably in an ultrafiltration device (such as the "Centricon 30", available from Amicon Corp., Danvers, MA) .
- the sample After ultrafiltration the sample typically has a protein concentration of between about 0.04 and 0.70 mg/ml. Typically the PMT-containing fractions from several such concentration columns are pooled and further concentrated. The PMT obtained after the anion exchange and sample concentration steps is further purified by preparative scale isoelectric focussing. Isoelectric focussing involves placing the sample mixture in a stabilized pH gradient, across which a voltage is then applied. Each protein species migrates electrophoretically toward the point in the pH gradient at which the net electrical charge of that protein species is zero. The pH at which a protein has a net electric charge of zero is called that protein's isoelectric point.
- pH gradient stabilizing media including, inter alia, sucrose solutions and polyacrylamide gels
- various methods of fractionating the pH gradient to recover proteins after isoelectric focussing can be employed.
- the pH gradient fractionation method should be chosen so as to be compatible with the gradient stabilizing medium.
- the preferred pH gradient stabilizing medium is a sucrose solution (density gradient) contained in a glass tube. Most preferably, the sucrose density gradient contains a pH gradient ranging from about pH 5 to about pH 6.
- the preferred gradient fractionation method is precisely controlled liquid flow through a stopcock. Fractions collected are tested for pH and PMT activity. Apparatuses, chemicals, and protocols for isoelectric focussing are available from several commercial sources.
- PMT isolated by the process of this invention is substantially free of other tobacco proteins, in that PMT is the predominant protein in the preparation.
- the few contaminating tobacco proteins in the preparation are separated from PMT by sodium dodecyl sulfate polyacrylamide gel electrophoresis ("SDS-PAGE") , according to standard techniques. In this way, sufficiently pure PMT for amino acid sequence analysis is obtained.
- Tobacco PMT is characterized by a molecular weight of between about 55 and 65 kilodaltons, as determined by SDS-PAGE, and a native isoelectric point of between about pH 5.0 and 6.0, as measured by isoelectric focussing. Tobacco PMT is further characterized by the ability to catalyze the transfer of the methyl group of S-adenosylmethionine to the delta amino group of putrescine, and by high substrate specificity for putrescine.
- the Michaelis-Menten constant K. is defined as the substrate concentration at which the initial reaction velocity is equal to one half of the maximal velocity of the reaction. K,,. values vary widely, even for separate enzyme species that catalyze the same reaction.
- Partially purified tobacco PMT is characterized by a K m for putrescine of between about 300 and 500 ⁇ M.
- Highly purified tobacco PMT of the present invention is characterized by a K,, for S-adenosylmethionine of between about 100 and 150 ⁇ m.
- protein bands are electroblotted onto glass microfiber sheets coated with a hydrophobic polycation, such as poly(4-vinyl-N-methylpyridinium) iodide, and visualized by a non-anionic agent such as fluorescamine.
- a hydrophobic polycation such as poly(4-vinyl-N-methylpyridinium) iodide
- a non-anionic agent such as fluorescamine.
- Another method involves electroblotting of proteins onto polyvinylidene difluoride membranes ("Immobilon-P", Millipore, Bedford, MA) and visualization of bands by an anionic dye such as a ido black (Bauw et al, "Alterations in the Phenotype of Plant Cells Studied by NH 2 -Terminal Amino Acid Sequence Analysis of Proteins Electroblotted from Two Dimensional Gel-Separated Total Extracts", Proc.
- the aforementioned techniques for transferring isolated proteins from electrophoretic gels and visualizing the transferred proteins are preferred. However, it will be appreciated by those skilled in the art that variations in materials and procedures used to prepare electrophoretically isolated proteins for sequence analysis are not excluded from the present invention.
- the bands constituting purified PMT are identified by apparent molecular weight (i.e., about 60 kD) . Following transfer of the protein bands from electrophoresis gel to membrane, and visualization of the transferred bands, the pieces of membrane bearing the individual bands of purified PMT are cut out precisely, so as to avoid contamination from any adjacent protein band.
- Tobacco PMT proteins comprise an amino acid sequence selected from SEQ ID N0:1, SEQ ID NO:2, and SEQ ID NO:3.
- SEQ ID N0:1 is from the “al” band (Fig. 5) .
- SEQ ID NO:2 is from the “a2" band (Fig. 5) .
- SEQ ID NO:3 is the consensus sequence of SEQ ID NO:l and SEQ ID NO:2.
- SEQ ID NO:2, SEQ ID NO:3) of the PMT proteins of this invention are used to design a set of oligonucleotides, one or more of which selectively hybridizes with PMT sequences in a tobacco root cDNA library. This selective hybridization is used to identify cDNA clones containing sequences encoding part or all of a PMT protein.
- a description of the design of oligonucleotide probes from amino acid sequences is presented in Chapter 11 of Sambrook et al. Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Press (1989) .
- oligonucleotide probes are carried out routinely with commercially available, automated equipment. Construction of cDNA libraries is now a routine task in molecular biology laboratories. See generally Chapter 8 of Sambrook et al., supra. Similarly, screening of cDNA libraries with oligonucleotide probes, to identify clones containing sequences of interest, is now commonplace and well within the capability of those of skill in the art. A description of the use of oligonucleotides for screening cDNA libraries is found in Chapter 11 of the laboratory manual by Sambrook et al., supra.
- the cDNA clones selected on the basis of hybridization with oligonucleotide probes are characterized as to size, presence of restriction sites, and nucleotide sequence.
- Such methods of DNA analysis are well described in, inter alia, publications by Sambrook et al., supra. and Ausubel et al. Short Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, New York (1989) . Any PMT cDNA clone obtained in this way can itself be used as a probe for identification of additional PMT cDNA clones.
- a tobacco (Nicotiana tabacum L. var. NK326) genomic library is commercially available (Clonetech Laboratories, Inc., Palo Alto, CA) . Such a genomic library is screened according to protocols supplied by the vendor, to obtain the chromosomal gene(s) encoding tobacco PMT.
- PCR polymerase chain reaction
- RNA PCR A PCR method preferred in the practice of the present invention is known as RNA PCR.
- RNA PCR There are two basic steps in RNA PCR: (1) reverse transcriptase synthesis of a first cDNA strand using RNA as a template in the presence of a reverse primer, and (2) Taq polymerase synthesis of the complementary cDNA strand, followed by Taq polymerase amplification of both strands, in the presence of both the forward and reverse primers.
- a PMT cDNA molecule may be obtained by application of the RNA PCR method, using tobacco root poly(A + ) RNA as a template with oligonucleotide primers based on known PMT partial amino acid sequences.
- this invention provides recombinant DNA molecules encoding tobacco PMT proteins.
- This invention also provides transgenic tobacco cells and plants stably transformed with recombinant DNA molecules, operably linked to regulatory sequences, that encode tobacco PMT proteins and that encode PMT antisense RNA molecules.
- a tobacco cell is transformed with an artificial PMT antisense transcriptional unit comprising a partial PMT cDNA sequence, a full-length PMT cDNA sequence, a partial PMT chromosomal sequence, or a full-length PMT chromosomal sequence, cloned in the antisense orientation, with appropriate operably linked regulatory sequences.
- Appropriate regulatory sequences include a transcription initiation sequence ("promoter”) , and a polyadenylation/transcription termination sequence.
- Cauliflower Mosaic Virus (CaMV) 35S promoter. See, e.g., Cornelissen et al., "Both RNA Level and Translation Efficiency are Reduced by Anti-Sense RNA in Transgenic Tobacco", Nucleic Acids Res. 17, pp. 833-43 (1989); Rezaian et al., "Anti-Sense RNAs of Cucumber Mosaic Virus in Transgenic Plants Assessed for Control of the Virus", Plant Molecular Biology 11, pp.
- CaMV Cauliflower Mosaic Virus
- CaMV 35S promoter for expression of PMT in the transformed tobacco cells and plants of this invention is preferred.
- Use of the CaMV promoter for expression of other recombinant genes in tobacco roots has been well described (Lam et al., "Site-Specific Mutations Alter In Vitro Factor Binding and change Promoter Expression Pattern in Transgenic Plants", Proc. Natl. Acad. Sci. USA 86, pp. 7890-94 (1989); Poulsen et al., "Dissection of 5' Upstream Sequences for Selective Expression of the Nicotiana plumbaginifolia rbcS-8B Gene", Mol. Gen. Genet. 214, pp. 16-23 (1988)).
- CaMV 35S promoter While use of the CaMV 35S promoter is preferred, it should be appreciated that other promoters are successfully used for expression of foreign genes in tobacco plants, and the use of promoters other than the CaMV 35S promoter falls within the scope of the present invention.
- transcription termination sequences are known. The source and identity of the transcription termination sequence is primarily a matter of convenience. For example, the nopaline synthase (“NOS”), octopine synthase (“OCS”) , and CaMV polyadenylation/transcription termination sequences are used for expression of foreign genes in transgenic tobacco plants, and would be useful for expression of PMT sequences. See, e.g., Rezian et al., supra, and Rodermel et al., supra.
- NOS nopaline synthase
- OCS octopine synthase
- CaMV polyadenylation/transcription termination sequences are used for expression of foreign genes in transgenic tobacco plants, and would be useful for expression of PMT sequences. See, e.g., Rezian et al., supra, and Rodermel et al., supra.
- Standard techniques such as restriction mapping. Southern blot hybridization, and nucleotide sequence analysis, are then employed to identify clones bearing PMT sequences in the antisense orientation, operably linked to the regulatory sequences (i.e., promoter and polyadenylation/transcription termination sequences) .
- regulatory sequences i.e., promoter and polyadenylation/transcription termination sequences.
- Any of the numerous known methods of tobacco cell transformation can be used in practicing the present invention. Methods for tobacco cell transformation are conveniently classified on the basis of whether or not they utilize components of the Agrobacterium system.
- AgroJba ⁇ teriu-n tumefasciens is a gram negative bacterium that harbors a plasmid with nucleotide sequences called "T-DNA" (for transferred DNA) , that are efficiently transferred and integrated into chromosomes of dicotyledonous plants (including tobacco) in nature, causing tumor growth on infected plants.
- T-DNA for transferred DNA
- This naturally-occurring vector system for integration of foreign DNA into plant chromosomes has been extensively studied, modified, and exploited for plant genetic engineering.
- Naked recombinant DNA molecules comprising PMT DNA sequences operably linked, in the sense or antisense orientation, to regulatory sequences are joined to-appropriate T-DNA sequences by conventional methods. These are introduced into tobacco protoplasts by polyethylene glycol techniques or by electroporation techniques, both of which are standard. Alternatively, such vectors comprising recombinant DNA molecules encoding PMT are introduced into live Agrobacterium cells, which then transfer the DNA into the tobacco plant cells (Rogers et al., "Gene Transfer in Plants: Production of Transformed Plants Using Ti Plasmid Vectors", Methods in Enzymology 118, pp. 627-40 (1986)) .
- Transformation by naked DNA without accompanying T-DNA vector sequences can be accomplished via fusion of tobacco protoplasts with DNA-containing liposomes or via electroporation.
- the PMT recombinant DNA molecules and vectors used to produce the transformed tobacco cells and plants of this invention will further comprise a dominant selectable marker gene.
- Suitable dominant selectable markers for use in tobacco include, inter alia, antibiotic resistance genes encoding neomycin phosphotransferase, hygromycin phosphotransferase, and chloramphenicol acetyltransferase.
- Another well-known dominant selectable marker suitable for use in tobacco is a mutant dihydrofolate reductase gene that encodes methotrexate-resistant dihydrofolate reductase (Deblaere et al., supra) .
- DNA vectors containing suitable antibiotic resistance genes, and the corresponding antibiotics are commercially available.
- Transformed tobacco cells are selected out of the surrounding population of non-transformed cells by placing the mixed population of cells into a culture medium containing an appropriate concentration of the antibiotic (or other compound normally toxic to tobacco cells) against which the chosen dominant selectable marker gene product confers resistance. Thus, only those tobacco cells that have been transformed will survive and multiply.
- Transformed cells are induced to regenerate intact, fertile, tobacco plants through application of tobacco cell and tissue culture techniques that are well known in the art.
- the method of plant regeneration is chosen so as to be compatible with the method of transformation. Verification of the stable presence and the orientation of the PMT sequence in the genome of putatively transgenic tobacco plants is by Mendelian inheritance of the PMT sequence, as revealed by standard methods of DNA analysis applied to progeny resulting from controlled crosses.
- the introduced PMT sequence is readily transferred to other tobacco varieties through conventional plant breeding practices and without undue experimentation.
- Buffer B 10 mM Tris/HCl, pH 7.5 1 mM EDTA (free acid) 20% (v/v) glycerol 2 mM DTT
- Leupeptin (1 mg/ml) was dissolved in distilled water and stored in 2.1 ml aliquots at -20°C until use.
- the harvested roots were washed with cold water and placed on a Buchner funnel, where water was removed by aspiration. The washed roots were stored frozen at
- the frozen roots were added to 2.5 liters of Buffer A that had been chilled into a frozen slurry, in a one-gallon Waring blender. The roots were mixed into the buffer slurry with a large spoon. The blender was started on a low speed setting, followed by additional homogenization at a medium speed setting. Care was taken to avoid permitting the temperature of the homogenate to rise above 3-5°C
- the extract was dispensed into centrifuge bottles, and insoluble debris was pelleted by centrifugation at 13,680 x g for 70 minutes at 4°C
- the supernatant was decanted, and its volume was 2.37 1. Approximately 0.77 g of DTT was added to the extract.
- the extract with 65% ammonium sulfate was stirred overnight at 4°C.
- the 40-65% ammonium sulfate fraction was pelleted by centrifugation at 27,500 x g for 70 minutes at 4°C, and the supernatant was discarded.
- the 40-65% ammonium sulfate precipitate was dissolved in Buffer B to yield a total volume of 200 ml, and then 17.53 g of NaCl was added and allowed to dissolve during stirring on ice. The dissolved 40-65% fraction with added NaCl was centrifuged at 47,800 x g for 30 min at 4°C, and the pellets were discarded.
- Each reaction tube contained the following: 12.5 ⁇ mol Tris/HCl pH 8.3 0.25 ⁇ mol EDTA 1.25 ⁇ mol 2-mercaptoethanol 0.9 ⁇ mol putrescine
- the radioactive product N-[ 14 C- methyl]putrescine
- One unit of PMT activity is defined as one nanomole of product formed per 30 min. , at 30°C.
- Negative controls were included with all PMT assays. Negative controls consisted of reaction mixtures minus enzyme, or reaction stopped with NaOH at time zero.
- the DEAE-Sepharose column was then washed at a flow rate of 1.5 ml/min with 70 ml Buffer C containing 10 mM NaCl until a stable 280 nm baseline was obtained.
- the column was then re-equilibrated with 50 ml of Buffer C without NaCl.
- the column was then raised to room temperature (24°C) , and the void volume of the column was replaced with Buffer C containing 5 mM putrescine (Sigma Chemical Co., St. Louis, MO, Cat. No. P7505, Lot No. 39F0039) .
- the column was held at 24°C with no flow for about l hour, and then PMT was eluted at 24°C with 632 ml of Buffer C containing 5 mM putrescine, at a flow rate of 0.7 ml/min (15 hours).
- the eluted PMT from the DEAE-Sepharose column was collected directly onto a column (1 cm x 3 cm) of omega-aminohexyl-Sepharose 4B ("AHS") (Sigma Chemical Co., St. Louis, MO, Cat. No. A8894) that was maintained at 4°C.
- AHS omega-aminohexyl-Sepharose 4B
- PMT was eluted from the AHS column with Buffer C containing 1.5 M NaCl, at a flow rate of 1.6 ml/min.
- Four fractions of 12-15 ml each were collected and assayed for PMT activity as described above.
- the first fraction (14.7 ml) contained more than 80% of the total PMT activity recovered from the AHS concentration column.
- PMT purified through the DEAE/AHS stage was further purified by isoelectric focussing.
- Preparative scale isoelectric focussing was performed with commercially available ampholytes (Pharmacia-LKB, Piscataway, NJ) in a sucrose density gradient (1.6 cm x 21 cm).
- the pH gradient was prepared according to the ampholyte vendor's instructions, and spanned the pH range from about 5.3 to about 6.3. Focussing was carried out for about 3 hours with application of from 1,000 to 4,000 volts (power between 1 and 4 watts) . Fractions of 1 ml each were collected after focussing, and the pH and PMT activity of each fraction was measured. Focussing and fraction collection were done at 4°C.
- Figure 4 is a dual plot of relative PMT activity and pH versus fraction number (i.e., location in the sucrose density gradient) , after isoelectric focussing.
- the data from the experiment depicted in Figure 4 indicated the isoelectric point of tobacco PMT to be approximately 5.7.
- the pi of tobacco PMT appeared to be as low as 5.0 and as high as 5.8.
- FIG. 1 shows SDS-PAGE protein band patterns displayed (upon silver staining) by samples at each of the steps in the PMT purification process.
- Samples on the gel were as follows: lanes 1 and 6, molecular weight standard proteins (listed above, in Brief Description of the Figures); lane 2, 40-65% ammonium sulfate fraction; lane 3, PMT activity peak fraction from phenyl-Sepharose column; lane 4, concentrated material from DEAE/AHS step; lane 5, PMT activity peak fraction from isoelectric focussing of concentrated material from DEAE/AHS step.
- the PMT band (indicated by arrow) that is prominent in the DEAE/AHS-purified material (lane 4) is barely visible in the material from the preceding hydrophobic interaction step (lane 3) .
- the apparent molecular weight of tobacco PMT was measured in an experiment that involved isolation of PMT on a non-denaturing electrophoresis gel loaded with PMT material that had been through the ammonium sulfate, phenyl-Sepharose, and DEAE/AHS/ultrafiltration stages of purification.
- the non-denaturing stacking gel buffer contained 0.27 M Tris/HCl (pH 6.8), 10% (v/v) glycerol, and 20 mM 2-mercaptoethanol.
- the nondenaturing 12.5% polyacrylamide resolving gel buffer contained 0.38 M Tris/HCl (pH 8.8), 10% (v/v) glycerol, and 12 mM 2- mercaptoethanol.
- a single lane from the non-denaturing gel was excised, cut in half along its length, and then cut into 3 mm slices. One half of each gel slice was placed directly into the standard PMT assay mixture, and the corresponding half of each gel slice was subjected to SDS-PAGE.
- the non-denaturing gel slice that displayed the highest PMT activity contained essentially a single protein with an apparent molecular weight of about 60 kD (Fig. 3) .
- Substrate specificity tests were carried out with highly purified tobacco PMT of the present invention.
- 1,3-Diaminopropane and 1,5-diaminopentane (chemical analogs of putrescine) phosphatidylethanolamine (a methyl group acceptor)
- N-methylputrescine the normal product of PMT
- putrescine (1,4-diaminobutane)
- putrescine (1,4-diaminobutane
- 1,3- diaminopropane, 1,5-diaminopentane, and the phosphatidylethanolamine were substituted for putrescine in the standard PMT assay (described above)
- no detectable amount of radioactive product was formed.
- N-methylputrescine was substituted for putrescine in the PMT assay, radioactive product formation was less than 6% of that observed with putrescine.
- Apparent 1 ⁇ values for the two PMT substrates, putrescine and S-adenosylmethionine, were determined by measuring PMT activity (as described above) at various rate-limiting concentrations of one substrate, while the other substrate was present in excess.
- the K influence, of partially purified tobacco PMT for putrescine was about 400 gM.
- the K.. of highly purified tobacco PMT for S- adenosylmethionine was about 125 ⁇ M.
- Tobacco PMT for sequence analysis was isolated via SDS-PAGE of material that had been subjected to the purification steps of ammonium sulfate fractionation, phenyl-Sepharose chromatography, DEAE-Sepharose chromatography with putrescine elution (followed by concentration via AHS and ultrafiltration) , and free ⁇ flow isoelectric focussing.
- the protein bands were electroblotted onto a polyvinylidene difluoride membrane ("Immobilon-P", Millipore, Bedford, MA) and visualized with amido black, by standard procedures.
- the piece of membrane bearing the "al" band see Fig.
- the sequence of the first 17 amino acids at the amino terminus of the tobacco PMT "al" band was found to be (SEQ ID N0:1): Leu Ser Xaa Asn Phe Leu Phe Gly Thr Ala Ser Ser Xaa Tyr Gin Tyr Glu.
- the "a2" band was the second of only two bands displaying the molecular weight of tobacco PMT (see Fig. 3) .
- the "a2" band yielded the following partial amino acid sequence (SEQ ID NO:2) : Leu Ser Ser Asn Phe Leu Phe Gly Thr Ala Ala Pro Tyr Tyr Gin Tyr Glu.
- the sequence of the first 15 amino acids of the 6.2 kD CNBR fragment of PMT was found to be (SEQ ID NO:6) : Asn Glu Pro Xaa Phe Val Ala lie Ser Gly Tyr Arg Asp Xaa Thr.
- the sequence of the first 20 amino acids of the 3 kD CNBR fragment of PMT was found to be (SEQ ID NO:7): Ala Asp lie Glu His Tyr Ser Lys Leu lie Asp Ala Leu Xaa lie Lys Gly lie Gin Phe.
- RNA PCR procedures were used to isolate PMT cDNA clones.
- the template in the RNA PCR procedures was poly(A + ) RNA isolated from tobacco roots.
- the starting material for poly(A + ) RNA preparation consisted of roots from hydroponically-grown tobacco plants (N. tabacum. var. Burly 21) .
- the first step in preparation of the poly(A + ) RNA was preparation of total RNA. Isolation of total tobacco root RNA was carried out using reagents and instructions from a commercially-available kit for preparation of total RNA (Stratagene, LaJolla, CA, Cat. No. 200345).
- Poly(A + ) RNA was isolated from the total RNA preparation using a commercially-available kit for preparation of poly(A + ) RNA (Pharmacia LKB, Piscataway, NJ, Cat. No. 27-9258- 01) .
- the oligonucleotide PCR primers were designed according to standard principles, utilizing the partial amino acid sequence data obtained from purified PMT protein, initially. In later experiments, primers were designed from sequences of previously isolated cDNA clones.
- RNA PCR procedures were carried out with a commercially available kit ("GeneAmp RNA PCR Kit", Perkin Elmer Cetus, Norwalk, CT) . The procedure was essentially according to the PCR kit vendor's recommendations. The vendor's protocol was modified as follows:
- PCR products selected for further analysis were cloned into the commercially available vector pBluescript II (SK+) (Stratagene) .
- An aliquot of the PCR product was treated with Klenow enzyme to generate blunt ends on the DNA.
- the Klenow reaction mixtures were as follows: approximately 1 ⁇ g of PCR-generated DNA, each of the four deoxynucleotide triphosphates at a final concentration of 80 ⁇ M each, 2.5 ⁇ l of 10X universal buffer (Stratagene) , 5 units of Klenow enzyme (Stratagene) , and water to yield a total volume of 25 ⁇ l.
- the Klenow reactions were run for 30 min. at room temperature and stopped by heat-inactivation at 75°C for 10 min.
- the PCR-generated DNA fragments were then ligated into pBluescript II (SK+) that been digested with restriction enzyme Smal.
- the ligation reaction mixtures were as follows: approximately 1 ⁇ g of blunt- ended DNA, approximately 0.2 ⁇ g of Smal-digested pBluescript II, 3 ⁇ l of 10X ligation buffer (Stratagene) , 12 units of T4 DNA ligase, and water to yield a total volume of 30 ⁇ l.
- 10X ligation buffer Stratagene
- T4 DNA ligase T4 DNA ligase
- Selected transformants were screened by PvuII restriction analysis of DNA prepared from cultures of the individual transformant colonies. This screening method was based on the fact that clones having the desired PCR product as an insert should yield a PvuII fragment approximately 0.5 kb larger than the PCR product. This is because there are PvuII restriction sites at nucleotide positions 529 and 977, flanking the pBluescript II multiple cloning site (MCS) , into which the PCR products were cloned. (See map of plasmid pBluescript II in the commercial vendor's product literature.) Clones selected in the PvuII screening were further analyzed by DNA sequence analysis.
- RNA PCR and cloning as described above.
- the template was tobacco root poly(A + ) RNA, and the forward and reverse primers were P-20 (SEQ ID NO:8) and P-22 (SEQ ID NO:9), respectively.
- the sequence design of primer P-20 was based on amino acids 13-20 of the 60 kD PMT protein.
- the sequence design of primer P-22 was base on amino acids 1-7 of the 15 kD CNBr fragment of the PMT protein.
- Preliminary DNA sequence analysis was carried out on clone PMT1.2.
- a deduced amino acid sequence encoded by one of the PMT1.2 reading frames showed strong homology (94%) to the N-terminal region of the 60 kD PMT protein.
- a deduced amino acid sequence encoded by PMT1.2 also showed strong homology (95%) to the 3 kD CNBr fragment (described above) which represents an internal region of the 60 kD PMT protein.
- Clone PMT-26 (approx. 1.2 kb) was obtained by RNA PCR and cloning as described above.
- the template was tobacco root poly(A + ) RNA, and the forward and reverse primers were P-24 (SEQ ID NO:10) and P-21 (SEQ ID NO:11), respectively.
- the sequence of primer P-24 was based on amino acids 4-10 of the intact 60 kD PMT protein and included a BamHI site at its 5' end.
- the sequence of primer P-21 was based on an N-terminal methionine and amino acids 1-6 of the 15 kD CNBr fragment of the 60 kD PMT protein.
- primer P-21 included an EcoRI site at its 5' end.
- the experiment was designed to obtain a cDNA clone encoding the region from amino acid #4, near the N-terminus of the 60 kD PMT protein, to amino acid #6 of the 15 kD CNBr fragment of that protein.
- Preliminary DNA sequence analysis was carried out on cDNA clone PMT-26.
- Clone PMT-26 encoded approximately two-thirds of the 60 kD PMT protein.
- the N-terminal region of a deduced amino acid sequence encoded by one of the PMT-26 reading frames showed strong homology to the N-terminal region of the 60 kD protein.
- the C-terminal region of that deduced amino acid sequence showed strong homology to the 3 kD CNBr fragment (described above) which represents an internal region of the 60 kD PMT protein.
- the PCR template was tobacco root poly(A + ) RNA
- the forward and reverse PCR primers were P-18 (SEQ ID NO:12) and P-23 (SEQ ID NO:13), respectively.
- the sequence of primer P- 18 was based on an N-terminal methionine plus amino acids 1 to 7 of a 15 kD cyanogen bromide fragment generated from the 60 kD protein purified as described above.
- the sequence of reverse primer P-23 consists of a poly(dt) region (20 deoxythimidines) , an EcoRI site, and 3 additional deoxythimidines at the 5' end.
- Clone PMT2-5 (approx. 1.5 kb) was obtained by utilizing RNA PCR and cloning techniques (essentially as described above) in combination with sequence information from the partial clone, PMT-26.
- the primer concentrations were 1.0 ⁇ M rather than 2.5 ⁇ M.
- first step cycle file specified 50°C rather than 55°C, and the last step cycle specified 30 min. rather than 10 min.
- the template was tobacco root poly(A + ) RNA, and the forward and reverse primers were P-38 (SEQ ID NO:14) and P-36 (SEQ ID NO:15), respectively.
- primer P-38 was based on a DNA sequence from the 51 region of clone PMT- 26 (described above) encoding the amino acids 4-11 of (SEQ ID NO:4) the N-terminal region of the 60 kD PMT protein.
- Primer P-36 was designed from the 3' region of DNA clone Q7. Primers P-38 and P-36 were both 100% homologous to their target sequences.
- a forward primer, P-37 was synthesized to add an Ncol restriction site and codons for an N-terminal methionine, an alanine and PMT amino acids 1-3 at the 5' end of clone PMT2-5.
- the sequence of primer P-37 was incorporated into the PMT2-5 DNA by means of standard DNA PCR techniques.
- the PMT2-5 DNA served as the template for the polymerase chain reaction, and the forward and reverse primers were P-37 (SEQ ID NO:16) and P-36 (SEQ ID NO:15), respectively.
- the DNA products from the PCR were cloned as described above. Clone PMT14-3 was obtained by this method.
- clone PMT14-3 encodes the complete 60 kD PMT protein with an additional alanine residue inserted immediately following the N-terminal methionine.
- This expected structure of clone PMT14-3 was confirmed by conventional sequence analysis.
- the sequence of clone PMT14-3 was found to be: (SEQ ID NO:17). What effect, if any, the inserted alanine residue will have on post- translational processing of the N-terminal methionine residue may be determined by sequence analysis of the recombinant PMT protein produced in host cells transformed with an expression vector carrying the PMT14-3 DNA insert in the sense orientation.
- Escherichia coli , PMT14-3 was deposited on March 11, 1993 and given the ATCC Designation 69253.
- Nicotiana tabacum leaves were inoculated with Agrobacterium tumefaciens containing the DNA sequence of SEQ ID NO:17, either in the 5' to 3' orientation or the 3' to 5' orientation as follows: pBI121: control plasmid, Kan r
- 1.2A3-3B plant transformed with 1.2kb fragment of PMT gene in antisense orientation
- 1.2A2-40 plant transformed with 1.2kb fragment of PMT gene in antisense orientation
- 1.2S3-15 plant transformed with 1.2kb fragment of PMT gene in sense orientation
- 1.2S4-16 plant transformed with 1.2kb fragment of PMT gene in sense orientation
- MOLECULE TYPE protein
- HYPOTHETICAL NO
- ANTI-SENSE NO
- MOLECULE TYPE DNA (genomic)
- HYPOTHETICAL YES
- ANTI-SENSE NO
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- HYPOTHETICAL YES
- ANTI-SENSE NO
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Environmental Sciences (AREA)
- Botany (AREA)
- Enzymes And Modification Thereof (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019950705408A KR960702865A (ko) | 1993-06-01 | 1994-06-01 | 퓨트레신 n-메틸트랜스퍼라제와, 이를 코딩하는 재조합 dna 분자 및 알칼로이드 함량이 감소된 유전자 변이된 담배 식물(putrescine n-methyltransfera-se, recombinant dna molecules encoding putrescine n-methyltranferase, and transgenic tobacco plants with decreased alkaloid content) |
EP94918175A EP0701614A1 (fr) | 1993-06-01 | 1994-06-01 | N-methyltransferase de putrescine, molecules d'adn de recombinaison codant cette derniere, et plants de tabac transgeniques a teneur reduite en alcaloides |
JP7501041A JPH09502601A (ja) | 1993-06-01 | 1994-06-01 | プトレッシンn−メチルトランスフェラーゼ、プトレッシンn−メチルトランスフェラーゼをコードする組換えdna分子、およびアルカロイド含量が減少したトランスジェニックタバコ植物 |
BR9406734A BR9406734A (pt) | 1993-06-01 | 1994-06-01 | Putrescina n-metiltransferase moléculas de dna recombinante que codifica putrescina n-metiltransferase e plantas de tabaco transgenicas com teor diminuido de alcaloide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7668193A | 1993-06-01 | 1993-06-01 | |
US08/076,681 | 1993-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994028142A1 true WO1994028142A1 (fr) | 1994-12-08 |
Family
ID=22133577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/006106 WO1994028142A1 (fr) | 1993-06-01 | 1994-06-01 | N-methyltransferase de putrescine, molecules d'adn de recombinaison codant cette derniere, et plants de tabac transgeniques a teneur reduite en alcaloides |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0701614A1 (fr) |
JP (1) | JPH09502601A (fr) |
KR (1) | KR960702865A (fr) |
CN (1) | CN1127530A (fr) |
BR (1) | BR9406734A (fr) |
WO (1) | WO1994028142A1 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998056923A1 (fr) * | 1997-06-12 | 1998-12-17 | North Carolina State University | Regulation de l'expression de l'enzyme quinolate-phosphoribosyl transferase |
US6907887B2 (en) | 2001-06-08 | 2005-06-21 | Vector Tobacco Ltd. | Modifying nicotine and nitrosamine levels in tobacco |
US6911541B2 (en) | 2000-08-30 | 2005-06-28 | North Carolina State University | Promoter fragment that is recognized by the product of the tobacco Nic gene |
EP1606404A2 (fr) * | 2003-03-12 | 2005-12-21 | Assay Designs, Inc. | Dosage de phosphokinase |
US7189570B2 (en) | 2000-11-07 | 2007-03-13 | North Carolina State University | Putrescine-n-methyltransferase promoter |
KR100792250B1 (ko) | 2006-06-09 | 2008-01-07 | 고려대학교 산학협력단 | 오이모자이크 바이러스의 증식 관련 단백질과 상호작용하는 신규한 메틸트랜스퍼라제 유전자 |
US9439452B2 (en) | 2005-05-11 | 2016-09-13 | Vector Tobacco Inc. | Reduced risk tobacco products and methods of making same |
US10405571B2 (en) | 2015-06-26 | 2019-09-10 | Altria Client Services Llc | Compositions and methods for producing tobacco plants and products having altered alkaloid levels |
US10777091B2 (en) | 2018-07-27 | 2020-09-15 | Joseph Pandolfino | Articles and formulations for smoking products and vaporizers |
US10878717B2 (en) | 2018-07-27 | 2020-12-29 | Joseph Pandolfino | Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1884545B (zh) * | 2005-06-24 | 2011-11-09 | 西南师范大学 | 利用基因工程技术培育托品烷类生物碱高产的颠茄及方法 |
CN102851288A (zh) * | 2012-06-30 | 2013-01-02 | 河南农业大学 | 烟碱生物合成pmt1基因启动子及其应用 |
JP2017508462A (ja) * | 2014-03-03 | 2017-03-30 | ノース カロライナ ステイト ユニヴァーシティ | タバコ近交系植物およびハイブリッド植物ならびにそれらから作られたタバコ製品 |
BR112021001364A2 (pt) * | 2018-07-26 | 2021-04-20 | Altria Client Services Llc | composições e métodos à base de engenharia de pmt para produzir plantas de tabaco e produtos tendo níveis de alcaloides alterados |
CN109321544A (zh) * | 2018-11-13 | 2019-02-12 | 中国烟草总公司郑州烟草研究院 | 一种提高烟叶提取物中腐胺n-甲基转移酶的提取方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0486214A2 (fr) * | 1990-11-14 | 1992-05-20 | Philip Morris Products Inc. | Putrescéine N-méthyltransférase, molécules d'ADN codant pour putrescéine N-Méthyltransférase, et des plantes de tabac transgéniques en contenu en nicotine modifié |
WO1993005646A1 (fr) * | 1991-09-13 | 1993-04-01 | Technology Management Services, S.A. | Reduction des niveaux de nicotine du tabac |
-
1994
- 1994-06-01 EP EP94918175A patent/EP0701614A1/fr not_active Withdrawn
- 1994-06-01 JP JP7501041A patent/JPH09502601A/ja active Pending
- 1994-06-01 BR BR9406734A patent/BR9406734A/pt not_active Application Discontinuation
- 1994-06-01 WO PCT/US1994/006106 patent/WO1994028142A1/fr not_active Application Discontinuation
- 1994-06-01 CN CN94192879A patent/CN1127530A/zh active Pending
- 1994-06-01 KR KR1019950705408A patent/KR960702865A/ko not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0486214A2 (fr) * | 1990-11-14 | 1992-05-20 | Philip Morris Products Inc. | Putrescéine N-méthyltransférase, molécules d'ADN codant pour putrescéine N-Méthyltransférase, et des plantes de tabac transgéniques en contenu en nicotine modifié |
WO1993005646A1 (fr) * | 1991-09-13 | 1993-04-01 | Technology Management Services, S.A. | Reduction des niveaux de nicotine du tabac |
Non-Patent Citations (1)
Title |
---|
HIBI N., ET AL.: "Gene expression in tobacco low-nicotine mutants", THE PLANT CELL, vol. 6, no. 5, May 1994 (1994-05-01), pages 723 - 735 * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1304576C (zh) * | 1997-06-12 | 2007-03-14 | 北卡罗来纳州大学 | 喹啉酸磷酸核糖转移酶表达的调节 |
CZ297379B6 (cs) * | 1997-06-12 | 2006-11-15 | North Carolina State University | Izolovaná DNA molekula, DNA konstrukt, rostlinná bunka a transgenická rostlina, peptid, zpusob prípravy transgenické rostlinné bunky, osivo transgenické rostliny, zpusob produkce tabákové rostliny a zpusob snízení a zvýsení exprese genu |
EP1457563A1 (fr) * | 1997-06-12 | 2004-09-15 | North Carolina State University | Régulation de l'expression de l'enzyme quinolate-phosphoribosyl transferase dans les plantes de tabac |
EA009898B1 (ru) * | 1997-06-12 | 2008-04-28 | Норт Каролина Стейт Юниверсити | Способы получения клеток трансгенных растений и трансгенных растений с повышенной продукцией хинолятфосфорибозил-трансферазы и табачный продукт |
US7425670B2 (en) | 1997-06-12 | 2008-09-16 | North Carolina State University | Methods and compositions for protein production in tobacco plants with reduced nicotine |
US7605308B2 (en) | 1997-06-12 | 2009-10-20 | North Carolina State University | Regulation of quinolate phosphoribosyl transferase expression |
US6423520B1 (en) | 1997-06-12 | 2002-07-23 | North Carolina State University | Regulation of quinolate phosphoribosyl transferase expression |
US7304220B2 (en) | 1997-06-12 | 2007-12-04 | North Carolina State University | Regulation of quinolate phosphoribosyl transferase expression |
WO1998056923A1 (fr) * | 1997-06-12 | 1998-12-17 | North Carolina State University | Regulation de l'expression de l'enzyme quinolate-phosphoribosyl transferase |
US7408098B2 (en) | 1997-06-12 | 2008-08-05 | North Carolina State University | Regulation of quinolate phosphoribosyl transferase expression |
US6911541B2 (en) | 2000-08-30 | 2005-06-28 | North Carolina State University | Promoter fragment that is recognized by the product of the tobacco Nic gene |
US7192771B2 (en) | 2000-08-30 | 2007-03-20 | North Carolina State University | Plant promoter sequence |
US7189570B2 (en) | 2000-11-07 | 2007-03-13 | North Carolina State University | Putrescine-n-methyltransferase promoter |
SG132542A1 (en) * | 2001-06-08 | 2007-06-28 | Vector Tobacco Ltd | Modifying nicotine and nitrosamine levels in tobacco |
US6907887B2 (en) | 2001-06-08 | 2005-06-21 | Vector Tobacco Ltd. | Modifying nicotine and nitrosamine levels in tobacco |
EP1606404A4 (fr) * | 2003-03-12 | 2006-04-12 | Assay Designs Inc | Dosage de phosphokinase |
EP1606404A2 (fr) * | 2003-03-12 | 2005-12-21 | Assay Designs, Inc. | Dosage de phosphokinase |
US9439452B2 (en) | 2005-05-11 | 2016-09-13 | Vector Tobacco Inc. | Reduced risk tobacco products and methods of making same |
US10709164B2 (en) | 2005-05-11 | 2020-07-14 | Vector Tobacco Inc. | Reduced risk tobacco products and methods of making same |
KR100792250B1 (ko) | 2006-06-09 | 2008-01-07 | 고려대학교 산학협력단 | 오이모자이크 바이러스의 증식 관련 단백질과 상호작용하는 신규한 메틸트랜스퍼라제 유전자 |
US10405571B2 (en) | 2015-06-26 | 2019-09-10 | Altria Client Services Llc | Compositions and methods for producing tobacco plants and products having altered alkaloid levels |
US10777091B2 (en) | 2018-07-27 | 2020-09-15 | Joseph Pandolfino | Articles and formulations for smoking products and vaporizers |
US10820624B2 (en) | 2018-07-27 | 2020-11-03 | Joseph Pandolfino | Articles and formulations for smoking products and vaporizers |
US10878717B2 (en) | 2018-07-27 | 2020-12-29 | Joseph Pandolfino | Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes |
US10897925B2 (en) | 2018-07-27 | 2021-01-26 | Joseph Pandolfino | Articles and formulations for smoking products and vaporizers |
US10973255B2 (en) | 2018-07-27 | 2021-04-13 | Cabbacis Llc | Articles and formulations for smoking products and vaporizers |
US11017689B2 (en) | 2018-07-27 | 2021-05-25 | Cabbacis Llc | Very low nicotine cigarette blended with very low THC cannabis |
Also Published As
Publication number | Publication date |
---|---|
CN1127530A (zh) | 1996-07-24 |
BR9406734A (pt) | 1996-01-30 |
KR960702865A (ko) | 1996-05-23 |
EP0701614A1 (fr) | 1996-03-20 |
JPH09502601A (ja) | 1997-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5668295A (en) | Protein involved in nicotine synthesis, DNA encoding, and use of sense and antisense DNAs corresponding thereto to affect nicotine content in transgenic tobacco cells and plants | |
US5684241A (en) | Purified tobacco protein involved in nicotine synthesis, DNA encoding, and use of sense and antisense DNAs corresponding thereto to affect nicotine content in tobacco plants | |
CA2287776C (fr) | Regulation de l'expression de l'enzyme quinolate-phosphoribosyl transferase | |
US5512466A (en) | Control of fruit ripening and senescence in plants | |
US6207881B1 (en) | Control of fruit ripening through genetic control of ACC synthase synthesis | |
EP0429458B1 (fr) | Procede pour provoquer la surproduction de lysine chez les plantes | |
US5145777A (en) | Plant cells resistant to herbicidal glutamine synthetase inhibitors | |
WO1997013843A9 (fr) | Production de plantes cerealieres transgeniques tolerantes aux stress hydrique et salin | |
AU7397796A (en) | Production of water stress or salt stress tolerant transgenic cereal plants | |
CA1338902C (fr) | Cellules vegetales resistant a un inhibiteur herbicide de type glutamine-synthetase | |
EP0701614A1 (fr) | N-methyltransferase de putrescine, molecules d'adn de recombinaison codant cette derniere, et plants de tabac transgeniques a teneur reduite en alcaloides | |
CA2264962C (fr) | Facteur de transcription regulant la voie de biosynthese du phenylpropanoide | |
AU576402B2 (en) | Plant cells resistant to herbicidal glutamine synthetase inhibitors | |
US20040244072A1 (en) | Leaf specific gene promoter of coffee | |
WO1997049727A1 (fr) | Promoteur aatt et facteur de transcription | |
JPH10512451A (ja) | グルタチオンs−トランスフェラーゼをコードするデオキシリボ核酸およびその使用 | |
AU609391C (en) | Plant cells resistant to herbicidal glutamine synthetase inhibitors | |
WO2001007592A2 (fr) | Plantes resistant aux herbicides et procedes de production desdites plantes | |
Shaver | Molecular analysis of transgenic maize modified for increased lysine biosynthesis | |
Evans | The effects of foreign genes in transgenic Thale cress (Arabidopsis thaliana | |
MXPA99011625A (en) | Regulation of quinolate phosphoribosyl transferase expression | |
AU5449301A (en) | Method for controlling water content of plant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 94192879.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): BR CN JP KR MW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994918175 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1994918175 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994918175 Country of ref document: EP |